S100A5: a marker of recurrence in WHO grade I meningiomas.
Some WHO grade I intracranial meningiomas resected from the same sites and with the same quality of resection (Simpson's grading scale) recur, while others do not. The reasons for this variability in occurrence of recurrence have not yet been determined. We therefore investigated the prognostic recurrence value of seven biological markers on a series of completely resected WHO grade I meningiomas. For this purpose, we analysed a series of 33 WHO grade I meningiomas totally resected between 1980 and 1990 (a follow-up of 10 years), including 14 cases of recurrence. The fixed tumour material from each meningioma was submitted to histochemical analyses targeting galectin-3 and its binding sites, the S100A5, S100A6 and S100B proteins, and cathepsin-B and -D. The levels of expression were assessed semi-quantitatively (in terms of the staining intensity and the labelling index) and submitted to uni- and multivariate analyses. Of all the markers investigated, only S100A5 expression can be associated with any significant prognostic value in the matter of recurrence. More particularly, the meningiomas with high levels of S100A5 staining intensity either did not recur, or recurred later than those with a low immunopositive S100A5 intensity (P = 0.004). Cox regression analyses demonstrated that this latter marker was associated with significant prognostic values independent of the patients' ages. Furthermore, the combination of the patients' ages and S100A5 staining intensity permitted the identification of a group with a particularly high risk of recurrence, that is, the patients younger than 55 and with meningiomas exhibiting low S100A5 intensities (P = 0.001). In conclusion, the S100A5 protein could play a role in the recurrence of totally resected WHO grade I meningiomas.
Hancq
S
S
Department of Neurosurgery, Erasmus Univesity Hospital, Brussels, Belgium.
Salmon
I
I
Brotchi
J
J
De Witte
O
O
Gabius
H-J
HJ
Heizmann
C W
CW
Kiss
R
R
Decaestecker
C
C
D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D018797:Cell Cycle Proteins; D002648:Child; D002675:Child, Preschool; D005260:Female; D037502:Galectin 3 / Q000096:biosynthesis; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008577:Meningeal Neoplasms / Q000378:metabolism / Q000473:pathology*; D008579:Meningioma / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology*; D009414:Nerve Growth Factors / Q000096:biosynthesis; D011247:Pregnancy; D011379:Prognosis; D000075383:S100 Calcium Binding Protein A6; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000096:biosynthesis*
D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D037502:Galectin 3; D009414:Nerve Growth Factors; D000075383:S100 Calcium Binding Protein A6; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C082355:S100A5 protein, human; C579160:S100B protein, human; C055351:S100A6 protein, human